| 2.7 0.07 (2.66%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.24  |
1-year : | 3.79 |
| Resists | First : | 2.77 |
Second : | 3.24 |
| Pivot price | 2.5  |
|||
| Supports | First : | 2.37 |
Second : | 2.13 |
| MAs | MA(5) : | 2.64 |
MA(20) : | 2.44 |
| MA(100) : | 3.02 |
MA(250) : | 5.43 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 71.3 |
D(3) : | 73.6 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 13.52 | Low : | 0.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ XAIR ] has closed below upper band by 7.1%. Bollinger Bands are 56.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.72 - 2.73 | 2.73 - 2.74 |
| Low: | 2.49 - 2.51 | 2.51 - 2.52 |
| Close: | 2.68 - 2.7 | 2.7 - 2.72 |
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Mon, 08 Sep 2025
Beyond Air, Inc. (XAIR) Stock: Orphan Drug Win Sparks Volatility Amid NeuroNOS Cancer Pipeline Hype - CoinCentral
Mon, 08 Sep 2025
Beyond Air’s Rise: Fluke or Everlasting? - StocksToTrade
Wed, 03 Sep 2025
Beyond Air, Inc. CEO Steve Lisi to Participate in H.C. Wainwright 27th Annual Global Investment Conference - Quiver Quantitative
Wed, 03 Sep 2025
Medical Device & Biopharma Leader Beyond Air Set for Major Investor Conference Presentation - Stock Titan
Wed, 13 Aug 2025
Beyond Air Inc (XAIR) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Expansion ... - Yahoo Finance
Tue, 12 Aug 2025
Beyond Air Revenue Soars to $1.8M as New Hospital Network Deal Opens Access to 4,350+ Facilities - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 8 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 8.5 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 189 (K) |
| Shares Short P.Month | 320 (K) |
| EPS | -10.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.11 |
| Profit Margin | 0 % |
| Operating Margin | -432.8 % |
| Return on Assets (ttm) | -64.7 % |
| Return on Equity (ttm) | -309.6 % |
| Qtrly Rev. Growth | 157.6 % |
| Gross Profit (p.s.) | -0.15 |
| Sales Per Share | 0.6 |
| EBITDA (p.s.) | -4.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.27 |
| PEG Ratio | 0 |
| Price to Book value | 1.27 |
| Price to Sales | 4.47 |
| Price to Cash Flow | -0.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|